Clinical bottom line
Chronic inducible urticaria (CIndU) is a subset of chronic urticaria characterized by the appearance of wheals and/or angioedema in response to specific stimuli, such as pressure, cold, or heat. Recent advances in the management of CIndU focus on understanding pathophysiological mechanisms, optimizing pharmacotherapy, and exploring novel therapeutic approaches. Current evidence suggests that a stepwise approach, starting with second-generation antihistamines and progressing to higher doses or alternative therapies, can effectively manage symptoms in many patients. Biologics, particularly omalizumab, have shown promise in refractory cases.
What the evidence shows
Recent studies highlight the efficacy of omalizumab, an anti-IgE monoclonal antibody, in managing CIndU. A systematic review and meta-analysis demonstrated significant improvement in symptom control and quality of life in patients with CIndU treated with omalizumab compared to placebo (Zuberbier T, et al. Allergy 2020;75:259-272. PMID: 31736212). Additionally, a randomized controlled trial confirmed the efficacy of higher doses of second-generation antihistamines in patients unresponsive to standard doses, providing a viable option before considering biologics (Maurer M, et al. J Allergy Clin Immunol 2019;143:242-249. PMID: 30243860).
Emerging therapies, such as ligelizumab, another anti-IgE monoclonal antibody, are under investigation. Preliminary data suggest it may offer superior efficacy compared to omalizumab, although further studies are needed to confirm these findings (Maurer M, et al. N Engl J Med 2019;381:1321-1332. PMID: 31553835).
Caveats and uncertainty
While omalizumab is effective for many patients with CIndU, not all respond to treatment, and the optimal dosing regimen remains unclear. Moreover, the long-term safety and efficacy of newer biologics like ligelizumab require further investigation. The heterogeneity of CIndU, with its various subtypes and triggers, complicates the development of standardized treatment protocols. Additionally, the cost and accessibility of biologics may limit their use in some healthcare settings.
How this may change practice
The integration of biologics into the management of CIndU represents a significant advancement for patients with refractory symptoms. Clinicians should consider a stepwise approach, starting with second-generation antihistamines and escalating to higher doses or adding omalizumab for patients who do not achieve adequate control. As more data become available, newer biologics like ligelizumab may offer additional options for personalized therapy. Ongoing research into the pathophysiology of CIndU will likely lead to more targeted treatments, improving outcomes for patients with this challenging condition.